Companion Animal Welfare

Dilated Cardiomyopathy in Dogs — Welfare and Management

Dilated cardiomyopathy (DCM) is a progressive heart muscle disease causing cardiac enlargement and reduced pumping capacity, leading to congestive heart failure and requiring long-term medical management.

Key Facts

Welfare Considerations

DCM causes progressive welfare deterioration that parallels the cardiac decline. In the preclinical phase — where the heart is enlarging but failure has not occurred — dogs may show only subtle exercise intolerance that owners attribute to aging or weight. Pimobendan started in the preclinical phase delays the onset of heart failure by a median of 9 months in Dobermans, representing a significant welfare benefit from early detection. Once congestive failure occurs, fluid accumulation in the chest causes breathlessness that is profoundly distressing: affected dogs are orthopnoeic (unable to lie flat), have increased respiratory effort at rest, and show anxiety from hypoxia. Diuretics provide rapid relief but require careful dose management to avoid dehydration. Arrhythmia management in Dobermans — who can experience sudden death from ventricular fibrillation even before heart failure — requires holter monitoring and antiarrhythmic therapy. Quality-of-life assessment at each stage of disease progression informs humane end-of-life decisions.

What You Can Do